Dr. Schleiss received his M.D. degree from the Oregon Health and Sciences University, Portland, Oregon. He completed his residency at Doernbecher Children’s Hospital, Oregon Health and Sciences University, Portland, Oregon and his Pediatric Infectious Diseases fellowship at Children’s Hospital Medical Center, University of Washington, Seattle, Washington. He also completed a fellowship in Molecular Medicine studying cytomegalovirus molecular genetics at the Fred Hutchinson Cancer Research Center, Seattle, Washington. His laboratory at the UMN Center for Infectious Diseases and Microbiology Translational Research is described at this link: http://www.cidmtr.umn.edu/investigators/schleiss/home.html. His research on CMV vaccines is described at this link: http://www.ahc.umn.edu/research/cytomegalovirus/index.htm
Intravaginal cytomegalovirus (CMV) challenge elicits maternal viremia and results in congenital transmission in a guinea pig model. Olejniczak MJ, Choi KY, McVoy MA, Cui X, Schleiss MR
. Virol J. 2011, 8:89. PMID: 21371319.
Could therapeutic vaccination of cytomegalovirus-seropositive persons prevent reinfection and congenital virus transmission? Schleiss MR
. J Infect Dis. 2011, 203(11):1513-6. PMID: 21592979.
A cytomegalovirus vaccine tames the troll of transplantation. Schleiss MR
. Lancet. 2011, 377:1216-8. PMID: 21481691.
Cytomegalovirus-induced sensorineural hearing loss with persistent cochlear inflammation in neonatal mice. Schachtele SJ, Mutnal MB, Schleiss MR,
Lokensgard JR. J Neurovirol. 2011, 17(3):201-11. PMID: 21416394.
Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV. McGregor A, Choi KY, Schleiss MR.
Virology. 2011, 410(1):76-87. PMID: 21094510.
Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines. Schleiss MR
. J Clin Invest. 2010, 120(12):4192-7. PMID: 21099107.
Update on the current status of cytomegalovirus vaccines. Sung H, Schleiss MR
. Expert Rev Vaccines. 2010, 9(11):1303-14. PMID: 21087108.
Prevention of maternal cytomegalovirus infection: current status and future prospects. Nyholm JL, Schleiss MR.
Int J Womens Health. 2010, 2:23-35. PMID: 21072294.
Screening newborns for congenital cytomegalovirus infection. Dollard SC, Schleiss MR
. JAMA. 2010, 304(4):407-8. PMID: 20664037.
Public health and laboratory considerations regarding newborn screening for congenital cytomegalovirus. Dollard SC, Schleiss MR,
Grosse SD. J Inherit Metab Dis. 2010, 33:S249-54. PMID: 20532822.
Child health research funding and policy: imperatives and investments for a healthier world. Hay WW Jr, Gitterman DP, Williams DA, Dover GJ, Sectish TC, Schleiss MR.
Pediatrics. 2010, 125(6):1259-65.
A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection. Crumpler MM, Choi KY, McVoy MA, Schleiss MR
. Vaccine. 2009, 27(31):4209-18. PMID: 19389443.
The impact of genome length on replication and genome stability of the herpesvirus guinea pig cytomegalovirus. Cui X, McGregor A, Schleiss MR, McVoy MA. Virology. 2009, 386(1):132-8. PMID: 19174305.
Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Cheeran MC, Lokensgard JR, Schleiss MR. Clin Microbiol Rev. 2009, 22(1):99-126. PMID: 19136436.
VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Schleiss MR. Curr Opin Mol Ther. 2009, 11:572-8. PMID: 19806506.